Positive dupilumab topline results announced from two Phase 3 trials in inadequately controlled moderate-to-severe atopic dermatitis patients
Regeneron Pharmaceuticals, Inc. and Sanofi have announced that two placebo-controlled Phase 3 studies evaluating investigational dupilumab in adult patients with inadequately controlled...